Dx Deals: New Deal Expands Reach of Oral Cancer Test to Dental Practices
Recently announced collaboration between Viome and Henry Schein allows dentists to offer sample collection for Viome’s assay to patients
Keeps You Up-to-Date on Lab Business and Competitive Strategy, Market Trends and Opportunities, and M&A and Investment Activity in Today’s Diagnostic Lab Industry
Recently announced collaboration between Viome and Henry Schein allows dentists to offer sample collection for Viome’s assay to patients
Though COVID-19 testing declines continue to negatively affect lab industry profits, the latest figures suggest the worst may be over.
Recent cases involve charges and judgments related to COVID-19 add-on tests, genetic testing fraud, and kickbacks.
A strategic partnership with Google enables more accurate whole genome sequencing with machine learning.
More multiplex COVID-19 combination tests emerge from premarket authorization pipeline.
Seven months into the year, there were already four reported deals valued at over $1 billion in 2023, as many as in all of 2022.
Proposed rule would require businesses to undergo even more stringent review to secure regulatory approval for such deals.
Centers for Medicare & Medicaid Services proposes TCET pathway to expedite Medicare Coverage of newly approved breakthrough devices.
Deciding whether to purchase or lease laboratory instrumentation involves a variety of factors.
Release of second-generation Cologuard test data and recently announced partnerships aim to position company well for the future.
Diagnostics companies that invested heavily in COVID-19 products are relying on M&A transactions to restructure and transition.